LAVA Therapeutics (NASDAQ:LVTX) Stock, Quote.Headers.trade-ideas

LAVA Therapeutics

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.

Stock_Whisper_Index_Logo_6-copy

Biotech

Exclusives

Tech

Media

Trading Ideas

AMSC

DWAC

JBLU

LVTX

SAVE

VERA

The Benzinga Stock Whisper Index provides a look at five stocks that saw increased attention from traders over the past week.

Benzinga&#39;s &#39;Stock Whisper&#39; Index: 5 Stocks Investors Secretly Monitor But Don&#39;t Talk About Yet (Donald Trump Has Re-Entered The Chat)

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

AFIB

AKTS

ALPN

ALTI

BMEA

CCTG

CISS

CMND

CNXC

COLB

CRGE

EPIX

IMMX

INSG

MRAI

ONCO

PCSA

PHUN

PROP

RDHL

RVSN

TSLA

VIRT

VSME

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.

Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

Intelligent Bio Solutions Inc. - Common Stock

INBS

U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday.

The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The S&amp;P 500 also rose, gaining, 0.26% to 4,881.28.

Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results

LAVA Therapeutics NV

WIIM

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are trading lower following recent strength. Worse-than-expected Q1 financial results and weak guidance from FedEx may have also weighed on stocks.

Piper Sandler analyst Paul Newsome maintains Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) with a Neutral and raises the price target from $254 to $293.

Price Target

Analyst Ratings

Piper Sandler Maintains Neutral on Arthur J. Gallagher, Raises Price Target to $293

Piper Sandler analyst Brian Mullan maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Neutral and raises the price target from $159 to $177.

Piper Sandler Maintains Neutral on Darden Restaurants, Raises Price Target to $177

CAPNU

Trading Halt: Halt status updated at 10:10:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Barclays analyst Jeffrey Bernstein maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Overweight and raises the price target from $180 to $192.

Barclays Maintains Overweight on Darden Restaurants, Raises Price Target to $192

Piper Sandler analyst Ryan Todd maintains Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) with a Neutral and lowers the price target from $168 to $145.

Piper Sandler Maintains Neutral on Marathon Petroleum, Lowers Price Target to $145

Cantor Fitzgerald analyst Kristen Kluska reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Neutral and maintains $152 price target.

Reiteration

SRPT

Cantor Fitzgerald Reiterates Neutral on Sarepta Therapeutics, Maintains $152 Price Target

Canadian medical cannabis giant Aurora Cannabis Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACB#TSX">ACB</a>) announced on Friday the appointments of CEO Miguel Martin to the additional role of executive chairman and outgoing chairman Ron Funk as lead independent director.
Both are backed by unanimous votes by the company's board of director and are effective immediately.
Martin has led Aurora as CEO and a director since 2020, driving the company&#8217;s financial recovery and successful business transformation.
Why It Matters: The board said combining the CEO and chairman roles will "promote strong and consistent leadership, directional clarity, and effective and efficient decision making — all of which better position Aurora to execute on its vision for global leadership."
&#8220;I am excited to take on this expanded role and equally thrilled that we will have the ongoing benefit of Ron&#8217;s extensive business experience, deep institutional knowledge and meticulous Board leadership and governance expertise as Lead Independent Director,&#8221; Martin said.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40512437/aurora-cannabis-dominates-30-of-canadas-medical-marijuana-exports-will-its-bold-int">Aurora Cannabis Dominates 30% Of Canada&#8217;s Medical Marijuana Exports: Will Its Bold International Expansion Pay Off?</a>
What's Next: Martin's expanded role allows him to lead in setting the board agenda. As lead independent director, Funk will continue to focus on ensuring the board functions effectively and independently of the company&#8217;s management.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20093254/ccc-oct-24-banner__1_-31.gif" alt="" class="wp-image-558446" /></a></figure>
<h1 class="wp-block-heading">Changes To Board Committee Compositions And Recent Moves</h1>
Michael Singer, who previously acted as executive chairman and interim CEO, was appointed to the Audit Committee and the Human Resource and Compensation Committee. Rajesh Uttamchandani was appointed to the HRCC and the Nominating and Corporate Governance Committee.
In the meantime, the company was working on innovating its operations via research in auto-flowering technology. Aurora received a U.S. Patent 12,002,546, "Methods of Determining Sensitivity to Photoperiod in Cannabis," allowing for its breeding program to identify and select for the auto-flowering trait.
The company said on Tuesday the innovative work provides foundational insight into the flowering mechanism in cannabis. The research would support future breeding strategies. It also could be utilized to advance outdoor cannabis cultivation in high-latitude regions, such as Canada.
ACG Price Action: Aurora's shares traded 0.87% lower at $5.72 per share Friday morning at publication.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40783070/auroras-cbd-lozenge-partnership-heres-where-to-find-the-new-product">Aurora&#8217;s CBD Lozenge Partnership: Here&#8217;s Where To Find The New Product</a></li>
</ul>

Cannabis

Entrepreneurship

Management

TSX:ACB

Aurora Cannabis CEO Takes On Dual Role: Here's What's Behind The Leadership Change

Europe&rsquo;s biggest automaker, Volkswagen (OTC: <a class="ticker" href="https://www.benzinga.com/stock/vwagy#OTC">VWAGY</a>) is considering plant closures for the first time in its 87-year-old history. But Volkswagen is merely a reflection of a struggling European auto industry that is currently challenged on many fronts, with its struggles being both the global competition and its declining appeal.&nbsp;
Europe&rsquo;s automotive industry is struggling with many issues simultaneously.&nbsp;
According to&nbsp;Bloomberg Intelligence, one in three European factories of carmaking behemoths, namely Volkswagen, Bayerische Motoren Werke Aktiengesellschaft (OTC: <a class="ticker" href="https://www.benzinga.com/stock/bmwyy#OTC">BMWYY</a>), Mercedes-Benz Group AG (OTC: <a class="ticker" href="https://www.benzinga.com/stock/mbgaf#OTC">MBGAF</a>)(OTC: <a class="ticker" href="https://www.benzinga.com/stock/mbgyy#OTC">MBGYY</a>), Stellantis N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stla#NYSE">STLA</a>) and Renault (OTC: <a class="ticker" href="https://www.benzinga.com/stock/rnlsy#OTC">RNLSY</a>) is underutilized.&nbsp;Meanwhile, Chinese automakers such as BYD (OTC: <a class="ticker" href="https://www.benzinga.com/stock/byddy#OTC">BYDDY</a>) are off to conquer Europe. To avoid tarrifs on China-made EVs, they are planning to make their own factories on the European continent.&nbsp;
Volkswagen is only one of the first victims.
Volkswagen Group CEO Oliver Blume&nbsp;openly spoke of the serious situation that Europe&rsquo;s automotive industry is facing with Germany in particular falling from grace as a competitive manufacturing location. Volkswagen has also fallen from grace in China, its single biggest market. During the first half of 2024, Volkswagen&rsquo;s deliveries in China dropped 7%&nbsp;YoY with group operating profit tumbling 11.4%&nbsp;to $11.2 billion. Volkswagen is losing out to local brands in China like BYD and those brands are now going for its home market.&nbsp;&nbsp;
Stellantis has also been hit by slowing demand in Europe.
In Italy, Stellantis is hitting the brakes. In response to the sales crisis, Stellantis halted production of its electric Fiat 500e for a month at its Mirafiori facility that is located near Turin. Stellantis also revealed that the site will be undergoing a significant transformation that will involve an investment worth&nbsp;&euro;100 million. Stellantis is expected to start making a hybrid version of the Fiat 500&nbsp;sometimes next year.&nbsp;
In addition to its European struggles, Stellantis is also facing a shrinking share in North America. During the first half of 2024, net revenues dropped 14% YoY while net profit took a 48% YoY plunge.
With Chinese EV makers navigating new roads, determined to conquer the world, simple cost-cutting measures won&rsquo;t do.&nbsp;
European automakers are having a hard time keeping up with Chinese EV makers. The increased tariffs that the EU imposed on Chinese EV makers led to significant backlash and concerns that this will make it more difficult for the EU to achieve its net-zero goals as Chinese EVs are more popular with consumers, both due to their more favorable pricing and greater features. Moreover, tarrifs are seen as&nbsp;a minor speed bump for an EV powerhouse like BYD.&nbsp;Regardless of their legacy, European automakers who fail to adapt quickly enough will be left on the sidelines as Chinese EV makers like BYD threaten to leave them in the dust.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

General

BMWYY

BYDDY

MERCEDES BENZ GROUP AG by Mercedes Benz Group AG

MBGAF

MERCEDES-BENZ UNSP / ADR by Mercedes Benz Group AG

MBGYY

RNLSY

STLA

VWAGY

Volkswagen's Crisis Is The Reflection Of Europe's Automotive Struggles

Cantor Fitzgerald analyst Louise Chen reiterates Oncolytics Biotech (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>) with a Overweight.

TSX:ONC

Cantor Fitzgerald Reiterates Overweight on Oncolytics Biotech

Piper Sandler analyst Ryan Todd maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Overweight and lowers the price target from $151 to $136.

Piper Sandler Maintains Overweight on Phillips 66, Lowers Price Target to $136

UBS analyst Ross Fowler maintains Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Neutral and raises the price target from $66 to $67.

UBS Maintains Neutral on Xcel Energy, Raises Price Target to $67

UBS analyst Daniel Ford maintains Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) with a Neutral and raises the price target from $90 to $91.

UBS Maintains Neutral on Southern, Raises Price Target to $91

Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) with a Overweight and maintains $160 price target.

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

A year after Meta Platforms introduced its artificial intelligence assistant, a picture is emerging of how people are using it—and how that differs from usage of OpenAI's ChatGPT, the leading conversational AI. Most people who use Meta AI daily do so through WhatsApp, according to a person who has seen recent internal data; the second biggest group arrives from Facebook. Few Instagram users are tapping Meta AI. Among monthly users, Facebook has a slight edge over WhatsApp, the person said.
<a href="https://www.theinformation.com/articles/whatsapp-dominates-meta-ai-use" title="https://www.theinformation.com/articles/whatsapp-dominates-meta-ai-use">https://www.theinformation.com/articles/whatsapp-dominates-meta-ai-use</a>

'WhatsApp Dominates Meta AI Use' - The Information

GameStop Corp&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock price is up 17.04% year-to-date but down 12.43% over the past month.
The Federal Trade Commission (FTC) recently slapped a fine on CEO Ryan Cohen, adding fuel to the fire, and further stoking the volatility that GameStop stock investors are used to.
Cohen agreed to <a href="https://www.benzinga.com/news/large-cap/24/09/40938804/gamestop-ceo-ryan-cohen-penalized-nearly-1m-over-wells-fargo-share-acquisition">pay almost $1 million</a> to settle charges from the FTC. His failure to report the acquisition of Wells Fargo shares promptly resulted in a sharp focus on his management.
This legal hiccup hasn't exactly helped GameStop&#8217;s stock price, and it's left investors wondering whether this meme stock has run out of extra lives.
<h2 class="wp-block-heading">GameStop Stock Chart Bearish: More &#8216;Game Over&#8217; Than &#8216;Level Up&#8217;? </h2>
GameStop stock's technical indicators are signaling a potential storm.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="458" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20085322/Screenshot-2024-09-20-at-6.22.51-PM.png" alt="" class="wp-image-558320" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20085322/Screenshot-2024-09-20-at-6.22.51-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20085322/Screenshot-2024-09-20-at-6.22.51-PM-300x218.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The stock's price sits at $19.51, well below critical moving averages:
<ul>
<li>Eight-day SMA: $20.57</li>
<li>20-day SMA: $21.58</li>
<li>50-day SMA: $22.74</li>
</ul>
With the stock trading below these moving averages, it's clear that GameStop is under intense selling pressure. The 200-day SMA is also closing in and if the trend continues the stock may drop below this average, signaling long-term bearishness.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/09/40826056/jim-cramer-agrees-gamestop-should-consider-operating-as-a-bank-and-labels-the-meme-stock-as-mass">Jim Cramer Agrees GameStop Should Consider Operating As A Bank And Labels The Meme Stock As &#8216;Massively Overvalued&#8217; SPAC</a>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="458" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20085559/Screenshot-2024-09-20-at-6.25.47-PM.png" alt="" class="wp-image-558330" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20085559/Screenshot-2024-09-20-at-6.25.47-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20085559/Screenshot-2024-09-20-at-6.25.47-PM-300x218.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The MACD (Moving Average Convergence Divergence) sits at a negative 0.78, confirming a bearish signal.
The Relative Strength Index (RSI) for GameStop stock is 37.89 and declining gradually, putting it in very close to the oversold territory. This could be a ray of hope for traders expecting a bounce back.
However, the stock is still struggling to break through any key resistance levels. This indicates further downside risks.
The Bollinger Bands (25) show a range of $18.81 &#8211; $24.47, with GameStop stock trading at $19.51, suggesting that the stock is sitting at the lower end of its range. The risk of it breaking lower increases unless some bullish catalyst intervenes.
<h2 class="wp-block-heading">Roaring Kitty Returns: A Meme Stock Spark? </h2>
Interestingly, meme stock hero Keith Gill, a.k.a. Roaring Kitty, recently resurfaced on social media, and GameStock stock&#8217;s price saw a small uptick in response.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://t.co/9xPMBKesNV">pic.twitter.com/9xPMBKesNV</a>
&mdash; Roaring Kitty (@TheRoaringKitty) <a href="https://twitter.com/TheRoaringKitty/status/1832086356849250635?ref_src=twsrc%5Etfw">September 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
However, these short-lived bumps are becoming less impactful as GameStop stock investors look for more sustainable growth rather than internet-driven hype.
GameStop may be oversold, but the bearish technical indicators outweigh any meme stock optimism. Unless a significant fundamental shift occurs, the stock seems poised for further declines. 
For now, GameStop stock bulls might have to wait until the next big catalyst.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40946963/bitcoin-worth-63-000-pulled-in-33-pack-of-trading-cards-at-gamestop-mind-boggling-story-go">Bitcoin Worth $63,000 Pulled In $33 Pack Of Trading Cards At GameStop &#8211; &#8216;Mind-Boggling&#8217; Story Goes Viral, Highlights Crypto Redemption Card</a></li>
</ul>
Image: Shutterstock

Gaming

Technicals

GameStop Stock Stuck In Level-Up Limbo: Can It Shake Off The Bearish Trend?

UBS analyst Julien Dumoulin-Smith maintains Alliant Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>) with a Neutral and raises the price target from $64 to $65.

UBS Maintains Neutral on Alliant Energy, Raises Price Target to $65

In the last three months, 17 analysts have published ratings on Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $197.53, along with a high estimate of $230.00 and a low estimate of $175.00. Experiencing a 0.94% decline, the current average is now lower than the previous average price target of $199.41. 
<img src="https://www.benzinga.com/files/images/story/2024/1726840947_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Builders FirstSource among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Stevenson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Rafe Jasrosich</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$198.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Tyler Batory</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Tyler Batory</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Collin Verron</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Stanley Elliott</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$195.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Tyler Batory</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Reuben Garner</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Alex Rygiel</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$187.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$178.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Rafe Jasrosich</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$180.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Tyler Batory</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$242.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$188.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Builders FirstSource. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Builders FirstSource compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Builders FirstSource's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BLDR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Builders FirstSource analyst ratings.</a>
<h2>All You Need to Know About Builders FirstSource</h2>
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
<h3>Builders FirstSource: A Financial Overview</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Builders FirstSource's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -1.6%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Builders FirstSource's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 7.72%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Builders FirstSource's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 7.43%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Builders FirstSource's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 3.14%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Builders FirstSource's debt-to-equity ratio is below the industry average. With a ratio of 1.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLDR

17 Analysts Assess Builders FirstSource: What You Need To Know

Throughout the last three months, 11 analysts have evaluated Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $161.27, a high estimate of $175.00, and a low estimate of $123.00. Observing a downward trend, the current average is 3.85% lower than the prior average price target of $167.73. 
<img src="https://www.benzinga.com/files/images/story/2024/1726840909_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Valero Energy's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Todd</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$123.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$131.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$171.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$172.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$173.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$156.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>John Royall</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$173.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Valero Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Valero Energy compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Valero Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Valero Energy's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VLO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Valero Energy analyst ratings.</a>
<h2>Discovering Valero Energy: A Closer Look</h2>
Valero Energy is one of the largest independent refiners in the United States. It operates 15 refineries, with a total throughput capacity of 3.2 million barrels a day in the US, Canada, and the United Kingdom. Valero also owns 12 ethanol plants with capacity of 1.6 billion gallons a year and holds a 50% stake in Diamond Green Diesel, which has the capacity to produce 1.2 billion gallons per year of renewable diesel.
<h3>Breaking Down Valero Energy's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Decline in Revenue: Over the 3 months period, Valero Energy faced challenges, resulting in a decline of approximately -0.06% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Valero Energy's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.54% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.41%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Valero Energy's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.39% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Valero Energy's debt-to-equity ratio is below the industry average. With a ratio of 0.42, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Valero Energy

UBS analyst Alex Kramm maintains FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) with a Neutral and raises the price target from $455 to $485.

UBS Maintains Neutral on FactSet Research Systems, Raises Price Target to $485

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aldeyra Therapeutics (ALDX – Research Report), LAVA ...

Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), LAVA Therapeutics (LVTX) and Crinetics Pharmaceuticals (CRNX)

LAVA Therapeutics (LVTX) has released an update. LAVA Therapeutics advances in cancer treatment with its innovative Gammabody&#xAE; platform, focusing o...

LAVA Therapeutics' Innovative Gammabody® Cancer Therapy

LAVA Therapeutics (LVTX) has released an update. LAVA Therapeutics N.V. held its Annual General Meeting where shareholders adopted the financial ac...

LAVA Therapeutics Shareholders Approve Key Resolutions

Arthur He CFA, an analyst from H.C. Wainwright, maintained the Buy rating on LAVA Therapeutics (LVTX – Research Report). The associated price targe...

LAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Underpin Buy Rating

LAVA Therapeutics GAAP EPS of -$0.31 beats by $0.03

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
LAVA Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/lvtx-stock-quote/">LVTX</a>) just reported results for the second quarter of 2024.<ul><li>LAVA Therapeutics reported earnings per share of -31 cents. This was above the analyst estimate for EPS of -36 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/lvtx-stock-earnings-lava-therapeutics-for-q2-of-2024/">LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024

LAVA Therapeutics (LVTX) has released an update. LAVA Therapeutics N.V. reports significant operating losses in its latest financial results, showc...

LAVA Therapeutics Faces Financial Hurdles

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on LAVA Therapeutics (LVTX – Research Report), with a price t...

Buy Rating Affirmed: LAVA Therapeutics' Financial Stability and Promising Clinical Pipeline

In a report released yesterday, Roger Song from Jefferies maintained a Buy rating on LAVA Therapeutics (LVTX – Research Report), with a price targe...

LAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Bolster Buy Rating

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
LAVA Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/lvtx-stock-quote/">LVTX</a>) just reported results for the second quarter of 2024.<ul><li>LAVA Therapeutics reported earnings per share of -31 cents. This was above the analyst estimate for EPS of -36 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/lvtx-stock-earnings-lava-therapeutics-for-q2-of-2024/">LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

LAVA Therapeutics

LAVA Therapeutics (LVTX) Forecast

LAVA Therapeutics (NASDAQ:LVTX) Stock, Quote.Headers.trade-ideas